Welcome to our dedicated page for OnKure Therapeutics SEC filings (Ticker: OKUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for OnKure Therapeutics, Inc. (OKUR) provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the Nasdaq Global Market. These documents offer detailed information about its precision oncology programs, financial condition, and capital markets activities, complementing the high-level descriptions found in press releases.
Through its periodic reports on Forms 10-K and 10-Q, OnKure describes its focus on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by current therapies. These filings expand on the company’s strategy around PI3Kα-targeted programs, including its lead candidate OKI-219 and its PI3Kα pan-mutant and other discovery-stage efforts, and include sections such as “Risk Factors” that outline scientific, clinical, regulatory, and financial risks.
Current reports on Form 8-K capture material events between periodic filings. For example, OnKure has filed 8-Ks to report quarterly financial results and to disclose entry into a sales agreement with Leerink Partners LLC for an at-the-market offering program of its Class A common stock. That agreement allows the company, subject to specified parameters and an effective shelf registration statement on Form S-3, to sell shares through Leerink Partners acting as sales agent, with compensation based on a percentage of gross proceeds.
On this page, users can review new and historical SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and registration statements such as Form S-3 referenced in the at-the-market program. Stock Titan’s tools apply AI-powered summaries to help explain the contents of lengthy filings, highlight key items like clinical development updates, capital raising arrangements, and risk disclosures, and make it easier to track how OnKure’s regulatory narrative evolves over time.
OnKure Therapeutics (OKUR) reported a wider quarterly loss as it advanced its lead oncology program. For Q3 2025, net loss was $14.7 million versus $11.6 million a year ago, driven by higher operating expenses. Research and development expense rose to $11.9 million and general and administrative expense to $3.6 million, reflecting increased personnel and share-based compensation. Interest income was $0.8 million.
Balance sheet capacity narrowed but remains solid for near-term plans. Cash and cash equivalents were $70.3 million at September 30, 2025, down from $110.8 million at year-end, with total assets of $72.8 million and stockholders’ equity of $66.4 million. Management believes existing cash will fund the current operating plan for at least 12 months from the financial statement issuance date.
Corporate update: The company completed its reverse recapitalization with Reneo on October 4, 2024 and a concurrent $65.0 million financing. As of November 5, 2025, shares outstanding were 12,861,672 Class A and 686,527 Class B.
OnKure Therapeutics, Inc. announced it issued a press release reporting financial results for the quarter ended September 30, 2025. The company furnished the release as Exhibit 99.1 alongside a business update.
The information under Item 2.02 is furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated into other filings unless specifically referenced.
Edward T. Mathers, a director of OnKure Therapeutics, Inc. (OKUR), acquired 4,125 fully vested restricted stock units (RSUs) on 09/30/2025 in lieu of a quarterly cash retainer under the company's Outside Director Compensation Policy. Each RSU converts into one share of Class A Common Stock. After the reported transaction, the reporting person beneficially owns 11,399 shares. The Form 4 was filed as a single reporting-person filing and bears a signature by an attorney-in-fact dated 10/02/2025.
Nicholas A. Saccomano, President and CEO and a director of OnKure Therapeutics, Inc. (OKUR), reported a routine transaction on 09/22/2025 in which 88 shares of Class A Common Stock were sold to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). The sale executed in multiple trades at prices ranging from $2.60 to $2.645, producing a weighted average sale price of $2.6235. Following the transaction, the reporting person beneficially owned 3,506 shares (certain of which remain as RSUs subject to vesting conditions). The Form 4 was signed by proxy on 09/24/2025.
OnKure Therapeutics CFO Jason A. Leverone reported a routine disposition of Class A common stock to cover tax withholding tied to RSU vesting. On 09/22/2025 the reporting person sold 303 shares at a weighted average price of $2.6235, leaving beneficial ownership of 12,603 shares. The filing explains the sale was automatic under the companys 2023 RSU Equity Incentive Plan and that RSUs represent contingent rights to receive one share upon vesting. The Form 4 was submitted under power of attorney on 09/24/2025.